Bibliography
- De Fronzo RA. Pathogenesis of type 2 diabetes: implications of metformin. Drugs 1999;21(Suppl 1):29-30
- Rendell M. The role of sulphonylureas in the management of type 2 diabetes mellitus. Drugs 2004;64(12):1339-58
- Saltiel AR, Olefsky JM. Thiazolidinediones in the treatment of insulin resistance and type 2 diabetes. Diabetes 1996;45(12):1661-9
- Kelley DE, Bidot P, Freedman Z, Efficacy and safety of acarbose in insulin-treated patients with type 2 diabetes. Diabetes Care 1998;21(12):2056-61
- Krssak M, Brehm A, Bernroider E, Alterations in postprandrial hepatic glycogen metabolism in type 2 diabetes. Diabetes 2004;53(12):3048-56
- Hoffmann-LaRoche. Indole and indazole derivatives as glycogen synthase activators. WO057959; 2011
- Hoffmann-LaRoche. Biaryloxymethylarene carboxylic acids as glycogen synthase activators. US0266856; 2004
- Hoffmann-LaRoche. biaryloxymethylarene carboxylic acids as glycogen synthase activators. US0255198; 2008
- Hoffmann-LaRoche. Biaryloxymethylarene carboylic acids. EP1819691; 2006
- Bolin DR, Qian Y, Chhabilbhai Takkar K, Biphenylcarboxylic acids and bioisosteres as glycogen synthase activators. US0118322; 2011
- Huwe A, Mazitschek R, Giannis A. Small molecules as Inhibitors of cyclin-dependent kinases. Angew Chem Int Ed 2003;42:2122-38
- Li R, Stafford JA. Kinase inhibitors drugs. Wiley: 2009